Northland Capital Partners Limited Morning Report: ImmuPharma (LON:IMM)

Lupuzor Pivotal Phase III Study Update

NORTHLAND VIEW

  • ImmuPharma has been informed by Simbec-Orion, the contract research organisation (CRO) conducting the Company’s Phase III trial for Lupuzor™, that the ‘database lock’ is expected on 6 April 2018.
  • Top line results for the trial are expected by mid-April 2018.
  • Lupuzor™ is the Company’s novel drug candidate for the treatment of Lupus, an autoimmune disease which affects c.5 million individuals worldwide.
  • ‘Database locking’ means that data collected from the trial will be secured and no changes/updates can be made to the database. Locking the database is necessary to prevent any changes to the data entry in randomized, blinded trials as it ensures the integrity of the data after un-blinding. Un-blinding the data is essential for the statistical analysis required to determine the trial outcome.

Tim McCarthy, Chairman, commented: “With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future.”

The database lock is a significant milestone for the clinical trial. Data collected during the trial forms the basis of subsequent safety and efficacy analysis. Once the data is locked the CRO can transfer the data for statistical analysis. Upon completion of the analysis ImmuPharma can determine if Lupuzor™ met the trial endpoints. Top-line readouts are expected in mid-April 2018 (previously Q1 2018). This is a minimal delay, common within the drug-development space, and allows the Company to make a thorough analysis of the trial data. With a £10 million raise completed in January, the Company remains in a strong cash position. Should Lupuzor™ successfully meet the trial endpoints, the Company will be in a strong negotiating position with potential partners.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because